Can I Take Vitamin B12 with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Stack It with Supplements?

MK-677 is a non-peptide, orally active ghrelin-receptor agonist that stimulates pulsatile growth hormone secretion from the pituitary. A 2-year randomized trial in 65 healthy older adults (aged 60 to 81) found that 25 mg/day of oral ibutamoren raised IGF-1 by approximately 40% above baseline and significantly increased lean body mass without altering fat mass at 12 months 1. The compound is not FDA-approved for any therapeutic indication 2.

Why Supplement Users Add B12 to an Ibutamoren Protocol

People who use MK-677 frequently combine it with vitamins, amino acids, and other agents to support recovery, metabolic health, and neurological function. Vitamin B12 enters this stack for two reasons. First, general interest in B12's role in energy metabolism and nerve conduction makes it a common baseline supplement. Second, a meaningful subset of MK-677 users also take metformin off-label to blunt the compound's tendency to raise fasting insulin and glucose, and metformin is one of the best-documented causes of acquired B12 deficiency 3.

The Research Gap

No randomized controlled trial, pharmacokinetic study, or case series has examined a direct interaction between ibutamoren and vitamin B12. This absence of data is itself informative: the two compounds operate through entirely different pathways, and no mechanistic basis for a direct interaction has been proposed in the literature.

Pharmacokinetics of MK-677: How It Moves Through the Body

Understanding MK-677's pharmacokinetics clarifies why a direct collision with B12 is unlikely. Oral bioavailability of ibutamoren is approximately 60 to 80% in animal models; human data are limited but consistent with near-complete absorption after oral dosing 4. Peak plasma concentration (Tmax) occurs at roughly 2 hours post-dose, and the terminal half-life in humans is approximately 5 to 8 hours, supporting once-daily evening dosing that aligns with natural GH pulsatility.

Hepatic Metabolism and CYP Enzymes

Ibutamoren undergoes hepatic metabolism via cytochrome P450 enzymes. Preclinical data suggest CYP3A4 involvement 4. Vitamin B12, by contrast, is not metabolized by CYP enzymes at all. It is absorbed in the terminal ileum through a receptor-mediated process requiring intrinsic factor, transported in plasma bound to transcobalamin II, and taken up by tissues via specific cobalamin receptors 5. These absorption and distribution systems are completely separate from the hepatic CYP machinery that handles ibutamoren.

No Shared Protein Binding

Drug interactions at the protein-binding level require two compounds to compete for the same binding sites on albumin or alpha-1-acid glycoprotein. Cobalamin circulates predominantly on transcobalamin II, a dedicated transport protein distinct from albumin and alpha-1-acid glycoprotein 5. Displacement interactions are not a plausible concern here.

Pharmacodynamics: Do MK-677 and B12 Affect the Same Targets?

Pharmacodynamic interactions occur when two substances modulate the same receptor, enzyme, or physiological system. MK-677 binds the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary, triggering GH release and downstream IGF-1 production 6. Vitamin B12 acts as a cofactor for two intracellular enzymes: methionine synthase, which remethylates homocysteine to methionine, and methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA in the mitochondria 7.

No Receptor Overlap

GHSR-1a and the two B12-dependent enzymes share no structural homology and no overlapping downstream signaling cascades. GH secretagogue receptor activation operates through Gq/G11 protein coupling and intracellular calcium mobilization. Methionine synthase and methylmalonyl-CoA mutase are cytosolic and mitochondrial enzymes, respectively, with no connection to G-protein-coupled receptor signaling.

Potential Complementary Effects on Nerve Health

One area where the two compounds could theoretically interact in a beneficial rather than harmful direction is peripheral nerve function. MK-677 raises IGF-1, and IGF-1 has documented neurotrophic properties 8. B12 deficiency is a recognized cause of subacute combined degeneration of the spinal cord, characterized by demyelination of the dorsal and lateral columns 9. Maintaining adequate B12 while on ibutamoren may support peripheral nerve health, though no clinical trial has tested this combination specifically.

The Metformin Bridge: The One Real Clinical Concern

This is where the conversation shifts from theoretical to practical. A measurable proportion of MK-677 users take metformin concurrently, either prescribed for type 2 diabetes or used off-label to counter ibutamoren's metabolic side effects. Metformin reduces vitamin B12 absorption by interfering with calcium-dependent binding of the intrinsic-factor-B12 complex to ileal receptors 3.

Quantifying the Depletion Risk

The DPPOS (Diabetes Prevention Program Outcomes Study) followed 857 participants on metformin for a median of 13 years and found that 4.3% developed B12 deficiency (<148 pmol/L) compared to 2.3% in the placebo group, with borderline-deficient levels (<221 pmol/L) in 19.1% of metformin users vs. 9.5% in controls (P<0.001) 10. A separate meta-analysis of 29 studies (N=8,089) found that metformin use was associated with a weighted mean reduction in serum B12 of 57 pmol/L and a 26% higher odds of deficiency 11.

What This Means for the MK-677 + Metformin User

If you are using both ibutamoren and metformin, B12 supplementation is not a casual add-on. The American Diabetes Association (ADA) 2024 Standards of Care state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with peripheral neuropathy or anemia" 12. That guideline was written for type 2 diabetes patients, but the mechanism of depletion is identical regardless of the indication for metformin use.

Vitamin B12 Dosing When Used Alongside MK-677

No guideline specifies a B12 dose for ibutamoren users specifically, so the clinical framework draws on general supplementation literature and the metformin-depletion data.

Oral Cyanocobalamin vs. Methylcobalamin

The two most common oral forms are cyanocobalamin and methylcobalamin. A 2017 Cochrane review found no statistically significant difference in B12 status outcomes between the two forms in healthy adults 13. For most users, cyanocobalamin at 500 to 1,000 mcg/day is adequate. Individuals with MTHFR polymorphisms or concerns about cyanide release (relevant mainly in tobacco amblyopia cases) may prefer methylcobalamin at equivalent doses.

When to Consider Higher Doses or Intramuscular Administration

If serum B12 falls below 148 pmol/L, oral doses of 1,000 to 2,000 mcg/day can reverse deficiency through passive diffusion, even in patients with impaired intrinsic factor function 14. Intramuscular hydroxocobalamin 1,000 mcg every 3 months is the standard NHS and many European protocols for established deficiency. The NIH Office of Dietary Supplements reports no established Tolerable Upper Intake Level for B12 because excess is excreted renally 15.

Timing Relative to MK-677

Because no pharmacokinetic interaction exists, there is no required separation window between B12 and ibutamoren. Most clinicians recommend taking MK-677 at night, 30 to 60 minutes before sleep, to align with the natural nocturnal GH surge. B12 can be taken at any time of day, though morning dosing is conventional and may marginally improve compliance.

Safety Profile of Vitamin B12: What the Data Show

Vitamin B12 has an excellent safety record at supplemental doses. The NIH states that no adverse effects have been associated with excess B12 intake from food or supplements in healthy individuals 15. Rare case reports of acneiform eruptions (B12-induced acne) exist at very high parenteral doses, and one population-based study found an association between high serum B12 (>600 pmol/L) and solid tumor diagnosis, though the elevated B12 was likely a consequence rather than a cause of malignancy 16.

No Known Toxicity Threshold

Unlike fat-soluble vitamins, cobalamin does not accumulate to toxic levels in soft tissues. Excess circulating B12 is filtered by the kidney and excreted in urine. This pharmacokinetic characteristic is why no Tolerable Upper Intake Level has been set by the Institute of Medicine or the European Food Safety Authority.

Known Side Effects of MK-677 That Are Unrelated to B12

Clinicians and users should be aware of the documented adverse effects of ibutamoren to avoid misattributing them to B12 or their combination.

Metabolic Effects

The primary clinical concern with MK-677 is insulin resistance. The 2-year trial by Murphy et al. Found a statistically significant increase in fasting glucose and insulin at the 25 mg/day dose 1. A 12-month study in 65 adults found meaningful elevations in HbA1c in participants with pre-existing impaired fasting glucose 17.

Water Retention and Edema

Ibutamoren raises GH, and supraphysiological GH promotes sodium and water retention through IGF-1-mediated renal tubular effects. Mild peripheral edema affects approximately 19% of users in clinical trial data 1.

Increased Appetite

Ghrelin receptor agonism increases appetite. This is pharmacologically expected and not a sign of B12 deficiency, which can independently cause appetite changes in severe cases.

Who Should Be Most Cautious About B12 Status on an Ibutamoren Protocol

Certain individuals carry higher baseline risk for B12 deficiency independent of any supplement interaction. The following framework helps identify who needs active monitoring rather than just passive supplementation.

Group 1: Concurrent metformin users. The DPPOS data place these individuals at roughly double the population risk of borderline deficiency 10. Baseline serum B12 before starting metformin, then annually, is reasonable clinical practice.

Group 2: Adults over 50. Gastric acid production declines with age, impairing protein-bound B12 release from food. Approximately 6% of adults over 60 in the United States are B12-deficient, rising to 20% in adults over 80 15. Crystalline B12 in supplements does not require gastric acid for absorption, making supplementation particularly effective in this group.

Group 3: Vegans and vegetarians. Dietary B12 comes almost exclusively from animal-source foods. Vegans who do not supplement have a near-universal risk of progressive depletion over months to years 7.

Group 4: Individuals with prior gastric surgery or autoimmune gastritis. Intrinsic factor production depends on gastric parietal cells. Damage to parietal cells from surgery, H. Pylori infection, or autoimmune destruction eliminates food-bound B12 absorption entirely, requiring supplemental crystalline B12 or intramuscular dosing.

Monitoring Protocol for MK-677 Users Taking Vitamin B12

A practical monitoring protocol combines the needs of the MK-677 protocol (IGF-1, fasting glucose, insulin) with B12-specific surveillance.

At Baseline (Before Starting MK-677)

Measure: fasting glucose, HbA1c, IGF-1, serum B12, complete blood count (to detect macrocytic anemia as an early marker of B12 deficiency), homocysteine (elevated levels can indicate functional B12 deficiency even when serum B12 appears normal) 18.

At 3 Months

Measure: fasting glucose, insulin, IGF-1. B12 recheck is not necessary at 3 months unless symptoms develop (paresthesia, cognitive changes, glossitis).

At 6 to 12 Months

Measure: full panel including serum B12 and homocysteine. If metformin is co-prescribed, annual B12 monitoring aligns with ADA guidance 12.

Red Flags Requiring Prompt Evaluation

Seek evaluation promptly if you develop tingling or numbness in the hands or feet, unexplained fatigue disproportionate to sleep quality, macrocytic anemia on CBC, or serum B12 below 148 pmol/L on any test. These findings do not confirm ibutamoren toxicity, but they do signal a need to reassess the full protocol.

Practical Guidance: How to Combine Vitamin B12 and MK-677 Safely

The clinical picture is straightforward. There is no pharmacokinetic or pharmacodynamic reason to avoid combining B12 with MK-677. The combination is not a risky one.

For most users, 500 to 1,000 mcg/day of oral cyanocobalamin taken in the morning alongside food is sufficient to maintain B12 status. Users who also take metformin should treat B12 supplementation as a protective measure rather than optional, given the DPPOS depletion data 10. Users over 50, vegans, or anyone with a history of gastric pathology should confirm baseline serum B12 before starting any protocol and recheck every 6 to 12 months.

Ibutamoren itself remains an unapproved research compound with meaningful metabolic risks, particularly for fasting glucose and insulin sensitivity. A board-certified physician should supervise any use of MK-677 in humans 2. The addition of vitamin B12 to that protocol carries no measurable risk and may provide meaningful protection in the subgroups described above. Confirm your serum B12 and homocysteine levels at baseline, then supplement accordingly.